Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Identifieur interne : 001B87 ( PubMed/Corpus ); précédent : 001B86; suivant : 001B88Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Auteurs : Toni K. Choueiri ; Bernard Escudier ; Thomas Powles ; Nizar M. Tannir ; Paul N. Mainwaring ; Brian I. Rini ; Hans J. Hammers ; Frede Donskov ; Bruce J. Roth ; Katriina Peltola ; Jae Lyun Lee ; Daniel Y C. Heng ; Manuela Schmidinger ; Neeraj Agarwal ; Cora N. Sternberg ; David F. Mcdermott ; Dana T. Aftab ; Colin Hessel ; Christian Scheffold ; Gisela Schwab ; Thomas E. Hutson ; Sumanta Pal ; Robert J. MotzerSource :
- The Lancet. Oncology [ 1474-5488 ] ; 2016.
English descriptors
- KwdEn :
- Aged, Anilides (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Carcinoma, Renal Cell (drug therapy), Carcinoma, Renal Cell (mortality), Carcinoma, Renal Cell (secondary), Everolimus (administration & dosage), Female, Follow-Up Studies, Humans, Kidney Neoplasms (drug therapy), Kidney Neoplasms (mortality), Kidney Neoplasms (pathology), Male, Middle Aged, Neoplasm Staging, Prognosis, Pyridines (administration & dosage), Survival Rate.
- MESH :
- chemical , administration & dosage : Anilides, Everolimus, Pyridines.
- drug therapy : Carcinoma, Renal Cell, Kidney Neoplasms.
- mortality : Carcinoma, Renal Cell, Kidney Neoplasms.
- pathology : Kidney Neoplasms.
- secondary : Carcinoma, Renal Cell.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Survival Rate.
Abstract
Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR, and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR tyrosine-kinase inhibitor treatment. Here, we report the final overall survival results from this study based on an unplanned second interim analysis.
DOI: 10.1016/S1470-2045(16)30107-3
PubMed: 27279544
Links to Exploration step
pubmed:27279544Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.</title><author><name sortKey="Choueiri, Toni K" sort="Choueiri, Toni K" uniqKey="Choueiri T" first="Toni K" last="Choueiri">Toni K. Choueiri</name><affiliation><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Escudier, Bernard" sort="Escudier, Bernard" uniqKey="Escudier B" first="Bernard" last="Escudier">Bernard Escudier</name><affiliation><nlm:affiliation>Institut Gustave Roussy, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Powles, Thomas" sort="Powles, Thomas" uniqKey="Powles T" first="Thomas" last="Powles">Thomas Powles</name><affiliation><nlm:affiliation>Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Tannir, Nizar M" sort="Tannir, Nizar M" uniqKey="Tannir N" first="Nizar M" last="Tannir">Nizar M. Tannir</name><affiliation><nlm:affiliation>University of Texas, MD Anderson Cancer Center Hospital, Houston, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mainwaring, Paul N" sort="Mainwaring, Paul N" uniqKey="Mainwaring P" first="Paul N" last="Mainwaring">Paul N. Mainwaring</name><affiliation><nlm:affiliation>Icon Cancer Care, Brisbane, Queensland, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Rini, Brian I" sort="Rini, Brian I" uniqKey="Rini B" first="Brian I" last="Rini">Brian I. Rini</name><affiliation><nlm:affiliation>Cleveland Clinic Foundation, Cleveland, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hammers, Hans J" sort="Hammers, Hans J" uniqKey="Hammers H" first="Hans J" last="Hammers">Hans J. Hammers</name><affiliation><nlm:affiliation>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Donskov, Frede" sort="Donskov, Frede" uniqKey="Donskov F" first="Frede" last="Donskov">Frede Donskov</name><affiliation><nlm:affiliation>Aarhus University Hospital, Aarhus, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Roth, Bruce J" sort="Roth, Bruce J" uniqKey="Roth B" first="Bruce J" last="Roth">Bruce J. Roth</name><affiliation><nlm:affiliation>Washington University in St Louis, St Louis, MO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Peltola, Katriina" sort="Peltola, Katriina" uniqKey="Peltola K" first="Katriina" last="Peltola">Katriina Peltola</name><affiliation><nlm:affiliation>Helsinki University Central Hospital Cancer Center, Helsinki, Finland.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Jae Lyun" sort="Lee, Jae Lyun" uniqKey="Lee J" first="Jae Lyun" last="Lee">Jae Lyun Lee</name><affiliation><nlm:affiliation>Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Heng, Daniel Y C" sort="Heng, Daniel Y C" uniqKey="Heng D" first="Daniel Y C" last="Heng">Daniel Y C. Heng</name><affiliation><nlm:affiliation>Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Schmidinger, Manuela" sort="Schmidinger, Manuela" uniqKey="Schmidinger M" first="Manuela" last="Schmidinger">Manuela Schmidinger</name><affiliation><nlm:affiliation>Medical University of Vienna, Vienna, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Agarwal, Neeraj" sort="Agarwal, Neeraj" uniqKey="Agarwal N" first="Neeraj" last="Agarwal">Neeraj Agarwal</name><affiliation><nlm:affiliation>Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah.</nlm:affiliation></affiliation></author><author><name sortKey="Sternberg, Cora N" sort="Sternberg, Cora N" uniqKey="Sternberg C" first="Cora N" last="Sternberg">Cora N. Sternberg</name><affiliation><nlm:affiliation>San Camillo and Forlanini Hospitals, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Mcdermott, David F" sort="Mcdermott, David F" uniqKey="Mcdermott D" first="David F" last="Mcdermott">David F. Mcdermott</name><affiliation><nlm:affiliation>Beth Israel Deaconess Medical Center, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Aftab, Dana T" sort="Aftab, Dana T" uniqKey="Aftab D" first="Dana T" last="Aftab">Dana T. Aftab</name><affiliation><nlm:affiliation>Exelixis, South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hessel, Colin" sort="Hessel, Colin" uniqKey="Hessel C" first="Colin" last="Hessel">Colin Hessel</name><affiliation><nlm:affiliation>Exelixis, South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Scheffold, Christian" sort="Scheffold, Christian" uniqKey="Scheffold C" first="Christian" last="Scheffold">Christian Scheffold</name><affiliation><nlm:affiliation>Exelixis, South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Schwab, Gisela" sort="Schwab, Gisela" uniqKey="Schwab G" first="Gisela" last="Schwab">Gisela Schwab</name><affiliation><nlm:affiliation>Exelixis, South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hutson, Thomas E" sort="Hutson, Thomas E" uniqKey="Hutson T" first="Thomas E" last="Hutson">Thomas E. Hutson</name><affiliation><nlm:affiliation>Texas Oncology-Baylor Sammons Cancer Center, Dallas, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Pal, Sumanta" sort="Pal, Sumanta" uniqKey="Pal S" first="Sumanta" last="Pal">Sumanta Pal</name><affiliation><nlm:affiliation>City of Hope National Medical Center, Duarte, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Motzer, Robert J" sort="Motzer, Robert J" uniqKey="Motzer R" first="Robert J" last="Motzer">Robert J. Motzer</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27279544</idno><idno type="pmid">27279544</idno><idno type="doi">10.1016/S1470-2045(16)30107-3</idno><idno type="wicri:Area/PubMed/Corpus">001B87</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B87</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.</title><author><name sortKey="Choueiri, Toni K" sort="Choueiri, Toni K" uniqKey="Choueiri T" first="Toni K" last="Choueiri">Toni K. Choueiri</name><affiliation><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Escudier, Bernard" sort="Escudier, Bernard" uniqKey="Escudier B" first="Bernard" last="Escudier">Bernard Escudier</name><affiliation><nlm:affiliation>Institut Gustave Roussy, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Powles, Thomas" sort="Powles, Thomas" uniqKey="Powles T" first="Thomas" last="Powles">Thomas Powles</name><affiliation><nlm:affiliation>Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Tannir, Nizar M" sort="Tannir, Nizar M" uniqKey="Tannir N" first="Nizar M" last="Tannir">Nizar M. Tannir</name><affiliation><nlm:affiliation>University of Texas, MD Anderson Cancer Center Hospital, Houston, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mainwaring, Paul N" sort="Mainwaring, Paul N" uniqKey="Mainwaring P" first="Paul N" last="Mainwaring">Paul N. Mainwaring</name><affiliation><nlm:affiliation>Icon Cancer Care, Brisbane, Queensland, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Rini, Brian I" sort="Rini, Brian I" uniqKey="Rini B" first="Brian I" last="Rini">Brian I. Rini</name><affiliation><nlm:affiliation>Cleveland Clinic Foundation, Cleveland, OH, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hammers, Hans J" sort="Hammers, Hans J" uniqKey="Hammers H" first="Hans J" last="Hammers">Hans J. Hammers</name><affiliation><nlm:affiliation>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Donskov, Frede" sort="Donskov, Frede" uniqKey="Donskov F" first="Frede" last="Donskov">Frede Donskov</name><affiliation><nlm:affiliation>Aarhus University Hospital, Aarhus, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Roth, Bruce J" sort="Roth, Bruce J" uniqKey="Roth B" first="Bruce J" last="Roth">Bruce J. Roth</name><affiliation><nlm:affiliation>Washington University in St Louis, St Louis, MO, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Peltola, Katriina" sort="Peltola, Katriina" uniqKey="Peltola K" first="Katriina" last="Peltola">Katriina Peltola</name><affiliation><nlm:affiliation>Helsinki University Central Hospital Cancer Center, Helsinki, Finland.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Jae Lyun" sort="Lee, Jae Lyun" uniqKey="Lee J" first="Jae Lyun" last="Lee">Jae Lyun Lee</name><affiliation><nlm:affiliation>Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Heng, Daniel Y C" sort="Heng, Daniel Y C" uniqKey="Heng D" first="Daniel Y C" last="Heng">Daniel Y C. Heng</name><affiliation><nlm:affiliation>Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Schmidinger, Manuela" sort="Schmidinger, Manuela" uniqKey="Schmidinger M" first="Manuela" last="Schmidinger">Manuela Schmidinger</name><affiliation><nlm:affiliation>Medical University of Vienna, Vienna, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Agarwal, Neeraj" sort="Agarwal, Neeraj" uniqKey="Agarwal N" first="Neeraj" last="Agarwal">Neeraj Agarwal</name><affiliation><nlm:affiliation>Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah.</nlm:affiliation></affiliation></author><author><name sortKey="Sternberg, Cora N" sort="Sternberg, Cora N" uniqKey="Sternberg C" first="Cora N" last="Sternberg">Cora N. Sternberg</name><affiliation><nlm:affiliation>San Camillo and Forlanini Hospitals, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Mcdermott, David F" sort="Mcdermott, David F" uniqKey="Mcdermott D" first="David F" last="Mcdermott">David F. Mcdermott</name><affiliation><nlm:affiliation>Beth Israel Deaconess Medical Center, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Aftab, Dana T" sort="Aftab, Dana T" uniqKey="Aftab D" first="Dana T" last="Aftab">Dana T. Aftab</name><affiliation><nlm:affiliation>Exelixis, South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hessel, Colin" sort="Hessel, Colin" uniqKey="Hessel C" first="Colin" last="Hessel">Colin Hessel</name><affiliation><nlm:affiliation>Exelixis, South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Scheffold, Christian" sort="Scheffold, Christian" uniqKey="Scheffold C" first="Christian" last="Scheffold">Christian Scheffold</name><affiliation><nlm:affiliation>Exelixis, South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Schwab, Gisela" sort="Schwab, Gisela" uniqKey="Schwab G" first="Gisela" last="Schwab">Gisela Schwab</name><affiliation><nlm:affiliation>Exelixis, South San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hutson, Thomas E" sort="Hutson, Thomas E" uniqKey="Hutson T" first="Thomas E" last="Hutson">Thomas E. Hutson</name><affiliation><nlm:affiliation>Texas Oncology-Baylor Sammons Cancer Center, Dallas, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Pal, Sumanta" sort="Pal, Sumanta" uniqKey="Pal S" first="Sumanta" last="Pal">Sumanta Pal</name><affiliation><nlm:affiliation>City of Hope National Medical Center, Duarte, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Motzer, Robert J" sort="Motzer, Robert J" uniqKey="Motzer R" first="Robert J" last="Motzer">Robert J. Motzer</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Anilides (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Carcinoma, Renal Cell (drug therapy)</term><term>Carcinoma, Renal Cell (mortality)</term><term>Carcinoma, Renal Cell (secondary)</term><term>Everolimus (administration & dosage)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Kidney Neoplasms (drug therapy)</term><term>Kidney Neoplasms (mortality)</term><term>Kidney Neoplasms (pathology)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Pyridines (administration & dosage)</term><term>Survival Rate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anilides</term><term>Everolimus</term><term>Pyridines</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Carcinoma, Renal Cell</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Survival Rate</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR, and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR tyrosine-kinase inhibitor treatment. Here, we report the final overall survival results from this study based on an unplanned second interim analysis.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27279544</PMID><DateCreated><Year>2016</Year><Month>07</Month><Day>11</Day></DateCreated><DateCompleted><Year>2017</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol.</ISOAbbreviation></Journal><ArticleTitle>Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.</ArticleTitle><Pagination><MedlinePgn>917-927</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(16)30107-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(16)30107-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR, and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR tyrosine-kinase inhibitor treatment. Here, we report the final overall survival results from this study based on an unplanned second interim analysis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this open-label, randomised phase 3 trial, we randomly assigned (1:1) patients aged 18 years and older with advanced or metastatic clear-cell renal cell carcinoma, measurable disease, and previous treatment with one or more VEGFR tyrosine-kinase inhibitors to receive 60 mg cabozantinib once a day or 10 mg everolimus once a day. Randomisation was done with an interactive voice and web response system. Stratification factors were Memorial Sloan Kettering Cancer Center risk group and the number of previous treatments with VEGFR tyrosine-kinase inhibitors. The primary endpoint was progression-free survival as assessed by an independent radiology review committee in the first 375 randomly assigned patients and has been previously reported. Secondary endpoints were overall survival and objective response in all randomly assigned patients assessed by intention-to-treat. Safety was assessed per protocol in all patients who received at least one dose of study drug. The study is closed for enrolment but treatment and follow-up of patients is ongoing for long-term safety evaluation. This trial is registered with ClinicalTrials.gov, number NCT01865747.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Between Aug 8, 2013, and Nov 24, 2014, 658 patients were randomly assigned to receive cabozantinib (n=330) or everolimus (n=328). The median duration of follow-up for overall survival and safety was 18·7 months (IQR 16·1-21·1) in the cabozantinib group and 18·8 months (16·0-21·2) in the everolimus group. Median overall survival was 21·4 months (95% CI 18·7-not estimable) with cabozantinib and 16·5 months (14·7-18·8) with everolimus (hazard ratio [HR] 0·66 [95% CI 0·53-0·83]; p=0·00026). Cabozantinib treatment also resulted in improved progression-free survival (HR 0·51 [95% CI 0·41-0·62]; p<0·0001) and objective response (17% [13-22] with cabozantinib vs 3% [2-6] with everolimus; p<0·0001) per independent radiology review among all randomised patients. The most common grade 3 or 4 adverse events were hypertension (49 [15%] in the cabozantinib group vs 12 [4%] in the everolimus group), diarrhoea (43 [13%] vs 7 [2%]), fatigue (36 [11%] vs 24 [7%]), palmar-plantar erythrodysaesthesia syndrome (27 [8%] vs 3 [1%]), anaemia (19 [6%] vs 53 [17%]), hyperglycaemia (3 [1%] vs 16 [5%]), and hypomagnesaemia (16 [5%] vs none). Serious adverse events grade 3 or worse occurred in 130 (39%) patients in the cabozantinib group and in 129 (40%) in the everolimus group. One treatment-related death occurred in the cabozantinib group (death; not otherwise specified) and two occurred in the everolimus group (one aspergillus infection and one pneumonia aspiration).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Treatment with cabozantinib increased overall survival, delayed disease progression, and improved the objective response compared with everolimus. Based on these results, cabozantinib should be considered as a new standard-of-care treatment option for previously treated patients with advanced renal cell carcinoma. Patients should be monitored for adverse events that might require dose modifications.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Exelixis Inc.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choueiri</LastName><ForeName>Toni K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escudier</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institut Gustave Roussy, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powles</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tannir</LastName><ForeName>Nizar M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>University of Texas, MD Anderson Cancer Center Hospital, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mainwaring</LastName><ForeName>Paul N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Icon Cancer Care, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rini</LastName><ForeName>Brian I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Foundation, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammers</LastName><ForeName>Hans J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donskov</LastName><ForeName>Frede</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roth</LastName><ForeName>Bruce J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Washington University in St Louis, St Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peltola</LastName><ForeName>Katriina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Helsinki University Central Hospital Cancer Center, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jae Lyun</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heng</LastName><ForeName>Daniel Y C</ForeName><Initials>DYC</Initials><AffiliationInfo><Affiliation>Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidinger</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Neeraj</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sternberg</LastName><ForeName>Cora N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>San Camillo and Forlanini Hospitals, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDermott</LastName><ForeName>David F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Beth Israel Deaconess Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aftab</LastName><ForeName>Dana T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Exelixis, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hessel</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Exelixis, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheffold</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Exelixis, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwab</LastName><ForeName>Gisela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Exelixis, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hutson</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Texas Oncology-Baylor Sammons Cancer Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Sumanta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>City of Hope National Medical Center, Duarte, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Motzer</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>METEOR investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01865747</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000813">Anilides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>1C39JW444G</RegistryNumber><NameOfSubstance UI="C558660">cabozantinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>9HW64Q8G6G</RegistryNumber><NameOfSubstance UI="D000068338">Everolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Transl Androl Urol. 2016 Dec;5(6):974-976</RefSource><PMID Version="1">28078236</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000813" MajorTopicYN="N">Anilides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002292" MajorTopicYN="N">Carcinoma, Renal Cell</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068338" MajorTopicYN="N">Everolimus</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007680" MajorTopicYN="N">Kidney Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>04</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27279544</ArticleId><ArticleId IdType="pii">S1470-2045(16)30107-3</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(16)30107-3</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B87 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001B87 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27279544
|texte= Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27279544" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |